Dermorphin Research: Frog-Skin Opioid Peptide Analysis

Dermorphin is a naturally occurring heptapeptide opioid agonist originally isolated from the skin secretions of the South American tree frog Phyllomedusa sauvagii, with the sequence H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2; it signals primarily through μ-opioid receptors and is scientifically notable as one of the early vertebrate peptides shown to contain a D-amino acid residue essential for activity (Broccardo et al., 1981, Eur J Biochem). For today’s research catalog, dermorphin is best understood through two safe, non-clinical lenses: peptide chemistry (stereochemistry, analog design, receptor pharmacology literature) and analytical method development (mass-spectrometric identification). This guide contains no administration instructions; catalog research material must be handled under applicable controlled-substance and laboratory regulations, never for human or animal use.

Discovery and historical context

Dermorphin was characterized in the early 1980s by Erspamer’s group during surveys of amphibian skin peptides. Its name combines derma (skin) and morphine, reflecting strong opioid-like activity reported in preclinical bioassays. The accompanying deltorphin peptides, isolated from related Phyllomedusa species, would later extend the same frog-skin peptide family toward δ-receptor selectivity (historical review, PMC6260176).

From a research-history standpoint, dermorphin mattered because vertebrate ribosomal peptides were expected to use only L-amino acids. The D-Ala at position 2 represented a documented post-translational epimerization event (or enzyme-catalyzed inversion in the biosynthetic pathway), opening a still-active area of peptide-biology research into how D-residues are installed and why they improve receptor binding or protease resistance.

Molecular identity and stereochemistry

Reference features to record in a lab notebook:

  • Sequence: H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 (seven residues; C-terminal amidated).
  • Key residue: D-alanine at position 2; replacing it with L-alanine sharply reduces opioid pharmacology in the literature, making stereochemistry an identity-critical attribute.
  • Receptor class: preferential μ-opioid receptor (MOR) ligand in preclinical binding and functional assays; related analogs have been profiled for μ-subtype selectivity.
  • Analytical identity: catalog records commonly list CAS 77614-16-5; suppliers should confirm this identifier and the exact salt form on the CoA.

Because the L-Ala diastereomer differs only in chirality, standard UV/HPLC alone can fail to distinguish the two; stereospecific chromatography, chiral analysis or MS/MS comparison with a qualified reference is the defensible approach. This point matters for any supplier audit: a mass match proves molecular mass, not configuration.

Pharmacology background in the literature

Early preclinical work in rodent bioassays reported high μ-receptor affinity and long-lasting antinociceptive actions, with potency comparisons relative to morphine depending on route and assay type; such numbers should be quoted only from the primary paper being reviewed, not reused as general marketing claims (PMC6260176). Research on synthetic dermorphin analogs (for example the tetrapeptide TAPS family) examined receptor subtype affinity, tolerance and withdrawal cross-reactivity in rodent models; those studies illustrate that opioid-receptor peptide agonists engage tolerance and dependence pathways, reinforcing why catalog material must remain a research-only reagent with controlled storage and access.

Analytical and detection research

A modern, legitimate research home for dermorphin chemistry is forensic and sports-doping analytical method development. LC-MS/MS methods have been published for detecting dermorphin and related diastereomers in biological matrices, with low picogram-per-milliliter detection limits and isotope-labeled internal standards; the method separates dermorphin from its unstable diastereomer and validates retention time, transitions and matrix effects (Guan et al., Anal Bioanal Chem 2013). Assay-development laboratories can adapt similar workflows for:

  • Peptide identity confirmation in supplier QC.
  • Stability studies under varying pH, temperature and storage conditions.
  • Method comparison between LC-MS/MS and immunoassay approaches.
  • Characterization of synthetic analog purity and stereochemical impurities.

Research applications and safe experiment design

Suitable nonclinical experiment designs include receptor binding-screening panels, structure-activity studies on the D-Ala position, synthesis-purification comparisons, and stability/analytical method development. Any cell-based or tissue assay should define receptor expression, vehicle controls and concentration-response ranges before results are interpreted. The molecule should never be discussed or handled as a self-administration compound; opioid-receptor peptides carry dependence and safety risks that make recreational or personal use outside this guide’s scope and outside lawful research authorization.

Sourcing, documentation and compliance

Because dermorphin has opioid pharmacology, procurement deserves extra discipline:

1. Verify legal status and license requirements in the destination jurisdiction before ordering; some regions treat opioid-active peptides as controlled or watch-list substances.

2. Request a supplier CoA with sequence confirmation, stereochemistry statement, purity method and lot traceability.

3. Store under lock and key with an inventory log, consistent with hazardous or controlled research materials handling.

4. Use institutional chemical-waste procedures for residues and consumables.

The broader Hanpro Peptides research catalog home lists related neuroscience and peptide reagents; a neighboring CNS peptide example for literature comparison is the DSIP sleep peptide research reagent, which belongs to a different peptide class and must not be mixed or compared as equivalent materials.

Frequently Asked Questions

What is dermorphin?

Dermorphin is a 7-residue amphibian-skin opioid peptide, H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, with preferential μ-opioid receptor activity in preclinical assays.

Where was dermorphin discovered?

It was isolated in the early 1980s from skin secretions of the South American tree frog Phyllomedusa sauvagii by Erspamer’s research group.

Why does the D-amino acid matter?

D-Ala at position 2 is essential for opioid activity; the L-Ala diastereomer behaves differently, so stereochemistry must be verified analytically rather than inferred from mass alone.

What kind of modern research uses it?

Analytical method development, receptor-binding chemistry, analog structure-activity work and stereoisomer impurity profiling are nonclinical applications suited to catalog material.

Is dermorphin approved for medical use?

It has no routine approved human clinical indication; opioid-peptide research literature describes preclinical models only. Catalog lots are research-use reagents.

What compliance checks apply to sourcing?

Verify local controlled-substance status, obtain lot CoA with stereochemistry evidence, store with restricted access and follow institutional waste and procurement rules.

How does it relate to DSIP?

They are unrelated peptide families; DSIP (delta sleep-inducing peptide) is a sleep-neuropeptide reagent, while dermorphin is an opioid chemistry subject. Never treat catalog listings as interchangeable.


Explore the research catalog: Hanpro Peptides research catalog home · related CNS reagent: DSIP sleep peptide · laboratory research only; opioid-peptide material subject to applicable legal controls, not for human or animal use.

Related Research Guides

Leave a Reply

Your email address will not be published. Required fields are marked *